Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19: JACC State-of-the-Art Review

Keyphrases

• Cardiovascular Mortality 100%
• Cardiovascular Morbidity 100%
• Influenza Vaccination 100%
• COVID-19 100%
• State-of-the-art Review 100%
• Influenza Vaccine 80%
• Cardiovascular Disease 40%
• Cardioprotection 40%
• Viral Respiratory Infections 40%
• Cardiovascular Outcome Trials 40%
• Primary Prevention 20%
• Lessons Learned 20%
• Healthcare Utilization 20%
• Trial Network 20%
• Secondary Prevention 20%
• Influenza-like Illness 20%
• International Trial 20%
• Risk Factors for Cardiovascular Diseases 20%
• Complication Risk 20%
• Respiratory Viruses 20%
• COVID-19 Pandemic 20%
• Virus Vaccine 20%
• Seasonal Influenza 20%
• Acute Cardiovascular Events 20%
• Morbidity Mortality 20%

Medicine and Dentistry

• Cardiovascular System 100%
• COVID-19 100%
• Influenza Vaccination 100%
• Cardiovascular Disease 50%
• Viral Respiratory Tract Infection 33%
• Influenza Vaccine 33%
• Primary Prevention 16%
• Secondary Prevention 16%
• Infection 16%
• Health Care Utilization 16%
• Seasonal Influenza 16%
• Virus Vaccine 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Coronavirinae 100%
• Diseases 100%
• Cardiovascular Disease 50%
• Live Attenuated Influenza Vaccine 33%
• Viral Respiratory Tract Infection 33%
• Influenza Vaccine 33%
• Respiratory Virus 16%
• Infection 16%
• Seasonal Influenza 16%
• Virus Vaccine 16%